Ken Griffin Argenx Se Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Argenx Se stock. As of the latest transaction made, Citadel Advisors LLC holds 33,400 shares of ARGX stock, worth $15.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
33,400
Previous 84,600
60.52%
Holding current value
$15.1 Million
Previous $32.2 Million
59.14%
% of portfolio
0.0%
Previous 0.01%
Shares
24 transactions
Others Institutions Holding ARGX
# of Institutions
356Shares Held
31.3MCall Options Held
212KPut Options Held
210K-
Price T Rowe Associates Inc Baltimore, MD5.5MShares$2.49 Billion0.27% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.19MShares$1.44 Billion1.93% of portfolio
-
Janus Henderson Group PLC London, X02.22MShares$1 Billion0.49% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD2.12MShares$955 Million0.51% of portfolio
-
Capital World Investors Los Angeles, CA1.86MShares$842 Million0.13% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $25B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...